Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Acute myeloid leukemia (AML) is a heterogenous disease with outcomes dependent upon
several factors, including patient age, karyotype, mutational status, and comorbid conditions …

Background Patients with relapsed or refractory acute myeloid leukemia (AML) with
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …

Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …

Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia
and has been associated with unfavorable clinical outcome. We hypothesized that down …

Abstract Clofarabine (2-chloro-2′-fluoro-deoxy-9-β-D-arabinofuranosyladenine) is a
second-generation nucleoside analog with activity in acute leukemias. As clofarabine is a …

The curability of acute myeloid leukaemia (AML) in a fraction of adult patients was
demonstrated a long time ago. Currently, the probability of cure is consistently above fifty per …

The article presents several guidelines on the management of acute myeloid leukemia in
adults, in London, England. These guidelines were based on the presentation of patients …